Navigation Links
Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
Date:12/9/2010

WALTHAM, Mass., Dec. 9, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

"The data suggest that NSCLC patients with elevated E-cadherin do better when treated with entinostat and erlotinib than erlotinib alone," said principal investigator Robert M. Jotte, M.D., Ph.D., director of thoracic oncology at Rocky Mountain Cancer Center Midtown Division in Denver and Developmental Co-Chair of US Oncology Lung Committee. "In the patients with elevated E-cadherin, the median survival was 9.4 months in those treated with erlotinib plus entinostat compared to 5.4 months in the patients treated with erlotinib plus placebo. Since patients with elevated E-cadherin represent approximately 40 percent of the overall non-small cell lung cancer population, this potentially is an important new treatment option that could improve outcomes for patients with NSCLC."

Results from ENCORE 401 will be presented tomorrow, Friday, December 10, 2010, in an oral presentation at the ASTRO 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.

"Using a biomarker to select patients based on the tumor biology can improve patient outcomes versus treating an unselected patient population," said Fred Hirsch, M.D., Ph.D., professor of medicine and pathology at the University of Colorado Health Sciences Center. "Restoring E-cadherin expression has been shown preclinically to increase sensitivity to EGFR inhibitors thereby restoring sensitivity to the standard of care treatment. E-cadherin, which can be measured easily in tumors, is therefore a potentially relevant clinical biomarker to select patients for treatment with erlotinib plus entinostat."

The primary endpoint of the study was four-month progression free survival rate with progression free survival (PFS) and overall survival (OS) as additional endpoints. In the unselected patient population made up of 132 evaluable patients, entinostat plus erlotinib appeared comparable in terms of PFS and survival. In the E-cadherin high sub-group (N = 26), entinostat plus erlotinib was associated with improved PFS and survival. The median PFS for the patients in the E-cadherin high

group treated with entinostat and erlotinib was 3.7 months vs. 1.9 months for the group treated with placebo and erlotinib (Hazard ratio 0.55) with a p-value of 0.19. The median survival was 9.4 months in the subgroup treated with entinostat and erlotinib vs. 5.4 months for those treated with placebo and erlotinib (Hazard ratio 0.36) with a p-value of 0.03.

Entinostat/erlotinib was tolerable with no unexpected adverse events and a manageable safety profile.

"Directing therapy based on the individual biology of a patient's tumor is finally driving better outcomes for patients with lung cancer," said Joanna Horobin, M.D., president and chief executive officer of Syndax. "Having seen improvement in PFS and overall survival in patients with tumors expressing high levels of e-cadherin who received entinostat and erlotinib, we now have a clear path forward. We look to add to treatment options as we evaluate entinostat with erlotinib in further randomized studies to be initiated next year in a selected patient population of NSCLC patients with high levels of E-cadherin."

The abstract "Molecular Analysis Identifies A Subset Of Non-small Cell Lung Cancer Patients With Differential Sensitivity To Histone Deacetylase Inhibitor (hdaci) / Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (egfr-tki) Treatment" was accepted as a late-breaker and will be given as an oral presentation at a scientific session at 2:15 p.m. on Friday, December 10, 2010.

For more Information regarding the presentation please visit http://www.thoracicsymposium.org/.

About Non-Small Cell Lung Cancer (NSCLC) Non-small cell lung cancer, a disease in which malignant cells form in the tissues of the lungs, is the most common type of lung cancer. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Each year there are more than 200,000 cases of newly diagnosed advanced NSCLC. About 60% of patients present with advanced NSCLC, meaning it has spread beyond the lung, when they are seen by a doctor. The five-year survival rate is less than 10 percent for patients with advanced NSCLC.

About Entinostat Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. In addition to ENCORE 401, entinostat is being studied in numerous phase 2 clinical trials including a trial in advanced breast cancer patients in combination with aromatase inhibitors and in a Hodgkin's lymphoma trial as a single agent. Under a Cooperative Research and Development Agreement (CRADA) with the NCI, Entinostat also is being studied in multiple types of solid tumors and hematologic cancers.

Research has shown that HDACs are involved in the expression of various genes that regulate cell growth, differentiation and apoptosis. Such genes are frequently silenced in cancer cells through the over-expression of enzymes including HDACs. HDACs are therefore recognized as promising targets for cancer treatment. Further, studies have demonstrated that HDAC inhibition can significantly enhance anti-cancer activity when used in combination with a broad range of anti-cancer agents. The potential therefore exists to overcome tumor resistance to targeted agents.

About Syndax Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit www.syndax.com. Contact Information E. Blair Schoeb Syndax Pharmaceuticals, Inc Tel: 908-277-0386 bschoeb@syndax.com
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
Breaking Medicine News(10 mins):